324 related articles for article (PubMed ID: 35975322)
21. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
[TBL] [Abstract][Full Text] [Related]
22. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
23. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
[TBL] [Abstract][Full Text] [Related]
24. HERV-K activation is strictly required to sustain CD133+ melanoma cells with stemness features.
Argaw-Denboba A; Balestrieri E; Serafino A; Cipriani C; Bucci I; Sorrentino R; Sciamanna I; Gambacurta A; Sinibaldi-Vallebona P; Matteucci C
J Exp Clin Cancer Res; 2017 Jan; 36(1):20. PubMed ID: 28125999
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
26. Suppression of a cancer stem-like phenotype mediated by alpha-lipoic acid in human lung cancer cells through down-regulation of β-catenin and Oct-4.
Phiboonchaiyanan PP; Chanvorachote P
Cell Oncol (Dordr); 2017 Oct; 40(5):497-510. PubMed ID: 28677037
[TBL] [Abstract][Full Text] [Related]
27. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
28. CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer.
Kunihiro AG; Sarrett SM; Lastwika KJ; Solan JL; Pisarenko T; Keinänen O; Rodriguez C; Taverne LR; Fitzpatrick AL; Li CI; Houghton AM; Zeglis BM; Lampe PD
J Nucl Med; 2022 Nov; 63(11):1701-1707. PubMed ID: 35483965
[TBL] [Abstract][Full Text] [Related]
29. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2.
Huang Z; Shen G; Gao J
Clin Transl Oncol; 2021 Sep; 23(9):1743-1751. PubMed ID: 33721187
[TBL] [Abstract][Full Text] [Related]
30. PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma.
Thirusangu P; Ray U; Sarkar Bhattacharya S; Oien DB; Jin L; Staub J; Kannan N; Molina JR; Shridhar V
Oncogene; 2022 Aug; 41(33):4003-4017. PubMed ID: 35804016
[TBL] [Abstract][Full Text] [Related]
31. BAG3 directly stabilizes Hexokinase 2 mRNA and promotes aerobic glycolysis in pancreatic cancer cells.
An MX; Li S; Yao HB; Li C; Wang JM; Sun J; Li XY; Meng XN; Wang HQ
J Cell Biol; 2017 Dec; 216(12):4091-4105. PubMed ID: 29114069
[TBL] [Abstract][Full Text] [Related]
32. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K
Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953
[TBL] [Abstract][Full Text] [Related]
33. The effect and mechanism of hexokinase-2 on cisplatin resistance in lung cancer cells A549.
Xie S; Li X; Zhao J; Zhang F; Shu Z; Cheng H; Liu S; Shi S
Environ Toxicol; 2024 May; 39(5):2667-2680. PubMed ID: 38224486
[TBL] [Abstract][Full Text] [Related]
34. LXR inhibitor SR9243-loaded immunoliposomes modulate lipid metabolism and stemness in colorectal cancer cells.
Dianat-Moghadam H; Abbasspour-Ravasjani S; Hamishehkar H; Rahbarghazi R; Nouri M
Med Oncol; 2023 Apr; 40(6):156. PubMed ID: 37093287
[TBL] [Abstract][Full Text] [Related]
35. High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway.
Liu CC; Chou KT; Hsu JW; Lin JH; Hsu TW; Yen DH; Hung SC; Hsu HS
Int J Cancer; 2019 Oct; 145(8):2144-2156. PubMed ID: 30920655
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide inhibits the growth of cancer stem cells derived from small cell lung cancer by downregulating stem cell-maintenance factors and inducing apoptosis via the Hedgehog signaling blockade.
Chang KJ; Yin JZ; Huang H; Li B; Yang MH
Transl Lung Cancer Res; 2020 Aug; 9(4):1379-1396. PubMed ID: 32953511
[TBL] [Abstract][Full Text] [Related]
37. ASPM Activates Hedgehog and Wnt Signaling to Promote Small Cell Lung Cancer Stemness and Progression.
Cheng LH; Hsu CC; Tsai HW; Liao WY; Yang PM; Liao TY; Hsieh HY; Chan TS; Tsai KK
Cancer Res; 2023 Mar; 83(6):830-844. PubMed ID: 36638332
[TBL] [Abstract][Full Text] [Related]
38. Nr5a2 promotes cancer stem cell properties and tumorigenesis in nonsmall cell lung cancer by regulating Nanog.
Ye T; Li J; Sun Z; Liu Y; Kong L; Zhou S; Tang J; Wang J; Xing HR
Cancer Med; 2019 Mar; 8(3):1232-1245. PubMed ID: 30740909
[TBL] [Abstract][Full Text] [Related]
39. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein.
Huang M; Xiong H; Luo D; Xu B; Liu H
Exp Cell Res; 2020 Mar; 388(2):111876. PubMed ID: 31991125
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway.
Dong P; Xiong Y; Konno Y; Ihira K; Kobayashi N; Yue J; Watari H
J Exp Clin Cancer Res; 2021 Jun; 40(1):216. PubMed ID: 34174908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
